Cervical cancer is the second most common cancer in women under the age of 45: Chronic infection with high-risk oncogenic subtypes of the human papilloma virus (HPV) is the main etiological factor in cervical carcinogenesis. Surgery is the standard of care for the treatment of early-stage cervical cancer, while chemoradiation is the most common treatment modality for locally advanced disease. In the US, the approvals of Keytruda as a first line therapy and Tivdak as a second line therapy in 2021, completely altered the treatment paradigm for recurrent and distally metastatic disease. Prior to the approval of Keytruda in first line, patients received chemotherapy with Avastin, which remains the treatment of choice outside the US.
The publisher projects the global cervical cancer market to experience substantial growth during the forecast period. Multiple checkpoint inhibitors, both used as monotherapies and in combination with other agents are forecast to either launch or expand to additional lines of therapy. The launch of an antibody drug conjugate and a tumor infiltrating lymphocyte therapy are also forecast to occur during this period. This growth will be slightly tempered by a reduction of branded sales of some agents following the introduction of generic and biosimilar alternatives.
The report will enable you to:
The publisher projects the global cervical cancer market to experience substantial growth during the forecast period. Multiple checkpoint inhibitors, both used as monotherapies and in combination with other agents are forecast to either launch or expand to additional lines of therapy. The launch of an antibody drug conjugate and a tumor infiltrating lymphocyte therapy are also forecast to occur during this period. This growth will be slightly tempered by a reduction of branded sales of some agents following the introduction of generic and biosimilar alternatives.
Key Highlights
- The main drivers of growth include the anticipated approval and launch of 13 pipeline therapies, the approval of an agent currently marketed in the US across the remaining 7MM, and the label expansion of one currently marketed therapy across the 8MM during the forecast period
- The main barriers to growth in the 8MM are patent expiries including those of Avastin, Keytruda, Imfinzi and Tecentriq
- Among the late-stage pipeline products and marketed agents, immunotherapies are expected to dominate, however Tivdak is expected to be the market leading brand
- The most important unmet needs in the cervical cancer market include: the need for adjuvant therapy in the locally advanced setting, the need for novel agents other than immunotherapies, the need for approval of agents outside the US market, the need for fertility-sparing treatment options, and an increase in HPV vaccine uptake
KEY QUESTIONS ANSWERED
- 13 late-stage pipeline agents are expected to enter the cervical cancer market from 2022 onwards What impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
- What are the current unmet needs in cervical cancer, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
- What is the market outlook in the 8MM from 2020-2030? Considering major patent expiries, launch of new premium priced agents and expected label expansions
- What are the main corporate trends? Who are the current and future players?
Scope
- Overview of cervical cancer including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines
- Topline cervical cancer market revenue, annual cost of therapy, and major pipeline product sales in the forecast period
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting cervical cancer therapeutics sales in the 8MM
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III)
- Analysis of the current and future market competition in the global cervical cancer therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines
- Develop business strategies by understanding the trends shaping and driving the global cervical cancer therapeutics market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global cervical cancer market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Track drug sales in the global cervical cancer therapeutics market from 2020-2030
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
Table of Contents
1 Cervical Cancer: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
List of Tables
List of Figures
